一种新的治疗组合减缓了前列腺癌的增长速度,推迟了对患有有限复发性疾病的男子的荷尔蒙治疗。 A new treatment combo slowed prostate cancer growth and delayed hormone therapy in men with limited recurrent disease.

LUNAR研究发现,在立体体放射治疗(SBRT)之前,给予PSMA目标放射性放射疗法(177Lu-PNT2002),大大推迟了患有有限复发性疾病的男子前列腺癌的蔓延。 A phase 2 clinical trial, the LUNAR study, found that giving PSMA-targeted radioligand therapy (177Lu-PNT2002) before stereotactic body radiotherapy (SBRT) significantly delayed prostate cancer progression in men with limited recurrent disease. 在92名患有少量前列腺癌的男性中,接受组合治疗的患者的无进展生存时间中位数为17. 6至18个月,超过单独SBRT治疗的7. 4个月的两倍. Among 92 men with oligorecurrent prostate cancer, those receiving the combination therapy had a median progression-free survival of 17.6 to 18 months, more than double the 7.4 months seen with SBRT alone. 病人还推迟了约10个月开始荷尔蒙治疗,减少了受疲劳和骨折等副作用影响的风险。 Patients also delayed starting hormone therapy by about 10 months, reducing exposure to side effects like fatigue and bone loss. 在半数以上的综合治疗中,PSA水平下降了至少50%。 PSA levels dropped by at least 50% in over half of those on the combination treatment. 治疗是精心设计的,没有增加严重的副作用,而且似乎针对扫描中看不到的微小疾病。 The therapy was well-tolerated, with no increase in severe side effects, and appeared to target microscopic disease not visible on scans. 研究人员查明了可能预测治疗反应的潜在生物标志。 Researchers identified potential biomarkers that may predict treatment response. 虽然近三分之二的病人仍然在进步,但结果显示,及早使用有针对性的放射疗法,加上精确辐射,可以改善结果和生活质量。 While nearly two-thirds of patients still progressed, the results suggest early use of targeted radioligand therapy combined with precision radiation improves outcomes and quality of life. 调查结果在2025年美国辐射肿瘤学学会会议上作了介绍。 The findings were presented at the 2025 American Society for Radiation Oncology meeting.